Axa
MYGN icon

Axa’s Myriad Genetics MYGN Stock Holding History

Axa’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-86,787
Closed -$2.41M – 1335
2019
Q2 		$2.41M Sell
86,787
-16,000
-16% -$452K 0.01% 812
2019
Q1 		$3.41M Buy
102,787
+17,100
+20% +$521K 0.01% 745
2018
Q4 		$2.49M Buy
85,687
+43,087
+101% +$1.55M 0.01% 776
2018
Q3 		$1.96M Sell
42,600
-27,800
-39% -$1.24M 0.01% 883
2018
Q2 		$2.63M Sell
70,400
-5,900
-8% -$199K 0.01% 793
2018
Q1 		$2.25M Buy
76,300
+8,900
+13% +$301K 0.01% 830
2017
Q4 		$2.31M Buy
+67,400
New +$2.27M 0.01% 820
2016
Q3 		– Sell
-25,900
Closed -$793K – 1295
2016
Q2 		$793K Buy
+25,900
New +$900K ﹤0.01% 920
2015
Q3 		– Sell
-170,600
Closed -$5.8M – 1486
2015
Q2 		$5.8M Buy
170,600
+8,200
+5% +$279K 0.02% 557
2015
Q1 		$5.75M Sell
162,400
-70,020
-30% -$2.51M 0.02% 559
2014
Q4 		$7.92M Buy
232,420
+57,576
+33% +$2.04M 0.03% 444
2014
Q3 		$6.74M Sell
174,844
-7,890
-4% -$294K 0.03% 463
2014
Q2 		$7.11M Sell
182,734
-11,328
-6% -$421K 0.03% 468
2014
Q1 		$6.63M Sell
194,062
-54,905
-22% -$1.7M 0.03% 471
2013
Q4 		$5.22M Sell
248,967
-15,286
-6% -$387K 0.02% 514
2013
Q3 		$6.21M Buy
264,253
+130,387
+97% +$3.7M 0.03% 477
2013
Q2 		$3.6M Buy
+133,866
New +$3.88M 0.02% 551

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Axa's MYGN Position: Q3 2019 in Review

Axa sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 86,787 shares — an estimated $2.41M sold.

Axa first reported a position in MYGN in Q2 2013 and held it in 17 quarters. The position peaked at $7.92M in Q4 2014. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

  • Axa reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
  • Axa sold 86,787 Myriad Genetics shares in Q3 2019, an estimated $2.41M.
  • Axa first reported a position in Myriad Genetics in Q2 2013 and held it in 17 quarters.
  • Axa's Myriad Genetics position peaked at $7.92M in Q4 2014.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Axa's 13F filing for Q3 2019, filed 14 Nov 2019.